Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.At the end of the year, Shanghai launched a big action in the field of mergers and acquisitions. Today, the General Office of the Shanghai Municipal People's Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027) (hereinafter referred to as the Action Plan).Yuan Shuai, the founder of the new productivity meeting room of Xinzhi School, said in an interview with the reporter of science and technology innovation board Daily that the Yangtze River Delta where Shanghai is located is an important place of integrated circuit industry, and the establishment of the 10 billion yuan integrated circuit design industry M&A fund is a strong support for Shanghai's semiconductor design industry.
In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.Bu Rixin, a partner of Chuangdao Investment Consulting, said in an interview with the science and technology innovation board Journal that the 10 billion M&A fund is mainly aimed at the "integrated circuit design industry", which may be related to the end of the IPO dividend period of chip design companies.The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.
Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.A 10 billion yuan M&A fund for biomedical industry will also be set up.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
Strategy guide
12-13